Clinical implications of molecular markers in acute myeloid leukemia
The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow u...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
European journal of haematology
Year: 2019, Jahrgang: 102, Heft: 1, Pages: 20-35 |
| ISSN: | 1600-0609 |
| DOI: | 10.1111/ejh.13172 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1111/ejh.13172 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13172 
|
| Verfasserangaben: | Sabine Kayser, Mark J. Levis |
| Zusammenfassung: | The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. We here discuss the utility of molecular markers in AML in prognostication and treatment decision making, specifically highlighting the aberrations included in the current WHO classification. |
|---|---|
| Beschreibung: | First published: 10 September 2018 Gesehen am 24.07.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1600-0609 |
| DOI: | 10.1111/ejh.13172 |